| abstract |
The present invention relates to siRNA molecules and their use in methods and pharmaceutical compositions for inhibiting ORAI1 gene expression. The present invention also relates to the use of said siRNAs molecules in the treatment and/or prevention of eye diseases characterized by increased ORAI1 gene expression and/or activity, preferably, said eye diseases are conjunctivitis and/or eye allergies, such as seasonal Allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis. |